Cat. #161785
OV-3331 cell line
Cat. #: 161785
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from ascites of patient diagnosed with adenocarcinoma at specific time points at diagnosis and relapse
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de Luniversité de Montréal
Primary Citation: Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: OV-3331 cell line
- Alternate name: OV-3331
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from ascites of patient diagnosed with adenocarcinoma at specific time points at diagnosis and relapse
- Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 6; Carboplatin/Taxol/CEP0906A2203E1/Doxorubicin
- Morphology: Formed loose aggregates rather than solid spheroids
- Growth properties: Adherent
- Crispr: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell lines spontaneously derived from ascites of patient diagnosed with adenocarcinoma
- Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
- Additional notes: Patient 3331 did not undergo cytoreductive sugery. Patient was age 72 at diagnosis and no prior history of cancer. Treatment involved Carboplatin, Paclitaxel, and Epothilone B. Year of sampling was 2007
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Temperature: 37° C
- Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
- Cultured in antibiotics: Amphotericin B and Gentamicin
References
- Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
- 10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
- 101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
- 21(20):7697. PMID: 33080952
